JPMorgan Chase & Co. Analysts Give Fresenius Medical Care AG & Co. (Pref) (FME) a €95.60 Price Target

Fresenius Medical Care AG & Co. (Pref) (ETR:FME) has been assigned a €95.60 ($113.81) price objective by equities researchers at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, December 29th. The firm presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 6.98% from the stock’s current price.

A number of other brokerages have also weighed in on FME. Morgan Stanley set a €90.00 ($107.14) target price on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “neutral” rating in a research report on Monday, December 11th. Berenberg Bank set a €95.60 ($113.81) price target on Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research note on Wednesday, December 6th. S&P Global set a €95.00 ($113.10) price target on Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research note on Monday, November 6th. Credit Suisse Group set a €92.00 ($109.52) price target on Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a research note on Monday, November 6th. Finally, HSBC set a €85.00 ($101.19) price target on Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a research note on Wednesday, November 22nd. Ten analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of €90.17 ($107.34).

Fresenius Medical Care AG & Co. (FME) opened at €89.36 ($106.38) on Friday. Fresenius Medical Care AG & Co. has a 52-week low of €74.43 ($88.61) and a 52-week high of €92.50 ($110.12). The firm has a market capitalization of $27,530.00 and a PE ratio of 21.90.

COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/fresenius-medical-care-ag-95-60-price-target-at-jpmorgan-chase-co.html.

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply